Online drug ads are gaining on TV: study by Beth Snyder Bulik Wednesday, August 15, 2018 Digital drug ads are gaining on TV in patient awareness and influence, according to a newly released patient study.
July's big TV spenders Humira, Lyrica drop $25M each by Beth Snyder Bulik Tuesday, August 14, 2018 AbbVie’s Humira, along with Pfizer’s Lyrica and Xeljanz, each spent more than $25 million on TV advertising for July.
AbbVie, Roche, Pfizer cited for 'exploitative' patent strategy by Angus Liu Monday, August 6, 2018 AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.
AbbVie's Imbruvica and Mavyret pick up steam in Q2 by Eric Sagonowsky Friday, July 27, 2018 AbbVie is bracing for European biosimilar competition to Humira, but the drug is still continuing its upward trajectory.
FDA’s Gottlieb blames drugmakers for ‘anemic’ biosimilar market by Angus Liu Thursday, July 19, 2018 Patent litigation and long-dated payer contracts are among the “unacceptable” tactics Gottlieb criticized for stalling biosim competition.
Lilly’s Trulicity ad spend leapfrogs into June’s second slot by Beth Snyder Bulik Wednesday, July 18, 2018 But with six months down and six to go, Humira is on track to keep its pharma TV ad crown for 2018 with spending well ahead of 2017.
AbbVie Humira patents in Bermuda enable big tax savings: Reuters by Eric Sagonowsky Wednesday, June 20, 2018 AbbVie has stored dozens of Humira patents in Bermuda, allowing it to lower its corporate tax rate, according to Reuters.
AbbVie mishandles Humira death complaints: FDA by Angus Liu Monday, June 11, 2018 FDA inspectors found that AbbVie didn’t include historical death complaints for the same lot in its search system for its all-too-important drug Humira.
AbbVie's Humira, Merck's Keytruda and more: Top 10 drugs of 2024 by Eric Sagonowsky Thursday, June 7, 2018 Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.
After Abbvie's usual first, Sunovion's a new second in TV spend by Beth Snyder Bulik Wednesday, June 6, 2018 AbbVie's Humira held on to its ad spending crown yet again in May, but Sunovion's Latuda jumped up to knock Pfizer's Lyrica out of second place.
